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Background: Alopecia areata (AA) is an autoimmune disease resulting in hair loss with devastating psychosocial
consequences. Despite its high prevalence, there are no FDA-approved treatments for AA. Prior studies have
identiﬁed a prominent interferon signature in AA, which signals through JAK molecules.
Methods:A patientwith AAwas enrolled in a clinical trial to examine the efﬁcacy of baricitinib, a JAK1/2 inhibitor,
to treat concomitant CANDLE syndrome. In vivo, preclinical studieswere conducted using the C3H/HeJ AAmouse
model to assess the mechanism of clinical improvement by baricitinib.
Findings: The patient exhibited a striking improvement of his AA on baricitinib over several months. In vivo
studies using the C3H/HeJ mouse model demonstrated a strong correlation between resolution of the interferon
signature and clinical improvement during baricitinib treatment.
Interpretation:Baricitinibmay be an effective treatment for AA andwarrants further investigation in clinical trials.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Alopecia areata (AA) is a polygenic autoimmune disease that results
in hair loss that ranges in presentation from circular patches on the
scalp that can often undergo spontaneous resolution to complete hair
loss thatmay persist for life. There are currently no FDA-approved treat-
ments for AA, and treatment regimens for patients with severe disease
are empiric and frequently unsatisfactory. Recent work in human
subjects has identiﬁed several genes underlying AA (Petukhova et al.,
2010; Betz et al., 2015), as well as a prominent interferon (IFN)t of Dermatology, Columbia
holas Ave., 3rd Floor, New York,
ermatology, Hadassah-Hebrew
no), zloto@cc.huji.ac.il
. This is an open access article undersignature in the AA scalp (Xing et al., 2014), inviting trials targeting
this pathway for treatment purposes.
Chronic atypical neutrophilic dermatosis with lipodystrophy
and elevated temperature (CANDLE) syndrome (OMIM 256040) is a
monogenic autoinﬂammatory syndrome that was initially described in
2010 (Torrelo et al., 2010). Patients present within the ﬁrst six months
of life with recurrent episodes of fever, periocular erythema and
edema, annular violaceous plaques (Supplementary Fig. 1) and
lipodystrophy (Torrelo et al., 2010; Ramot et al., 2011; Liu et al., 2012).
Alopecia is not reported as a part of the CANDLE phenotype or other
immunoproteasome-related disorders (Torrelo et al., 2010; Agarwal
et al., 2010; Arima et al., 2011). Mutations have been discovered in
PSMB8, whose gene product is a component of the immunoproteasome,
in some, but not all patients, with CANDLE syndrome (Liu et al., 2012).
There are currently no well-established treatments for this rare orphan
disease. Whole genome expression analysis of peripheral blood mono-
nuclear cells identiﬁed the IFN pathway as being highly dysregulated
in these patients (Liu et al., 2012), establishing a possible target for
the development of new treatments.the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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signatures, albeit as a result of different genetic mechanisms. Type I and
type II IFNs signal through cell surface receptors that initially activate
JAK kinases, speciﬁcally JAK1 and either TYK2 or JAK2, respectively.
Small molecule JAK inhibitors have been developed and are currently
available for myeloﬁbrosis (Verstovsek et al., 2010) and rheumatoid
arthritis (RA) (Fleischmann et al., 2012). This class of drugs offers the
convenience of being orally bioavailable when compared with biologic
inhibitors of IFNs, which require parenteral administration. Here,
we describe a patient enrolled in a clinical trial of baricitinib, an oral
JAK inhibitor with relative selectivity for JAK1 and JAK2, for CANDLE
syndrome who experienced dramatic resolution of his AA.
A 17-year-old man with chronic long-standing AA was enrolled
in a clinical trial examining the efﬁcacy of baricitinib for a proposed
IFN mediated autoinﬂammatory syndrome, CANDLE syndrome
(NCT01724580). The diagnosis of CANDLE syndrome was based on the
typical clinical features of widespread annular violaceous skin lesions
and the multisystemic inﬂammatory characteristics (Ramot et al., 2011)
and had been conﬁrmed by ﬁnding a homozygous mutation in PSMB8
(Liu et al., 2012). Prior to the trial, he had been treated for CANDLE syn-
drome with two courses of intravenous pulses of methylprednisolone
and oral methotrexate (10 mg/week). At the time of study initiation, he
had been taking oral prednisone at a dose of 12 mg/day.
The patient suffered from a chronic patch-type AA for seven years,
which involved mainly his occipital scalp. He had been treated with
dithranol cream and minoxidil in the past without improvement of his
alopecia. In the time preceding his enrollment in the trial, the patient
experienced progression of his disease to an ophiasis pattern, a form
of AA that is usually recalcitrant to treatment (Finner, 2011), despite
being on an immunosuppressive regimen for CANDLE syndrome.
2. Methods
2.1. Clinical Studies
Due to the observation that increased STAT-1 phosphorylation and a
strong IFN response signature are observed in CANDLE patients (Liu
et al., 2012), a treatment trial with the JAK 1/2 inhibitor baricitinib
was initiated at the National Institutes of Health (NCT01724580). The
patient was enrolled in this study and started to receive once-daily
oral baricitinib in September 2012, initially at a dose of 7 mg daily and
6 months later at 7 mg in the morning and 4 mg in the evening, with
gradual tapering of oral corticosteroids to 3 mg daily. Informed consent
was provided by the patient and his guardians. All forms and protocol
were approved by the NIDDK/NIAMS IRB, and the study number on
clinicaltrials.gov is NCT01724580.
2.2. Animal Studies
We performed three sets of in vivo experiments to determine the
mechanistic basis for treatment response of AA with baricitinib.
Baricitinib was obtained from MedKoo Biosciences (Chapel Hill, NC).
The C3H/HeJ graft-recipient mouse model of AA was used for these
experiments. C3H/HeJ mice spontaneously develop alopecia at a rate
of 10–20% by 6–18months of age. C3H/HeJ mice that receive skin grafts
of alopecic skin from donor alopecic C3H/HeJ mice develop the disease
95–100% of the time by 10 weeks post-transplant. Using the C3H/HeJ
grafted mouse model of AA, we ﬁrst conducted experiments to prevent
onset of disease by administering baricitinib at the time of grafting.
Brieﬂy, alopecic skin from a C3H/HeJ mouse that spontaneously devel-
oped hair losswas grafted onto 8–10week old C3H/HeJmice free of dis-
ease. At the time of grafting, an osmotic pump (Alzet) that administered
approximately 0.7 mg/day of baricitinib or placebo was implanted.
Osmotic pumps were changed monthly.
A time-to-event survival analysis for interval censored datawas per-
formed. The survival and interval packages in R were used to performlog-rank tests. The hypothesis that the survival distributions are equal
in the (n = 10) baricitinib-treated mice and (n = 10) placebo-treated
mice is rejected at the 5% level using Sun's score to perform an exact
log-rank two-sample test with the p-value of 0.0035.
We then conducted treatment experiments in the setting of
established AA in mice, using both systemic delivery and topical delivery
of baricitinib. C3H/HeJ recipients of alopecic C3H/HeJ mouse skin were
aged at least an additional 12 weeks to allow for near complete alopecia
prior to either implantation of osmotic pumps or topical treatment.
Osmotic pump administration was conducted in a similar manner as for
the prevention experiments. For topical treatment experiments, vehicle
control or 0.5% baricitinib was applied topically daily. For these experi-
ments, the R package nparLD was used to test the hypothesis that there
exists a treatment by time interaction. A F1–LD–F1 designwas employed.
The hypothesis of no interaction, i.e., parallel time proﬁles, is rejected at
the 5% level using both the Wald-type statistic and the ANOVA-type
statistic with the p-values of 5.80 × 10−22 and 3.74 × 10−15, respectively,
for the baricitinib-treated (n = 8) and placebo-treated (n = 8) groups.
At the indicated time points, skin sampleswere taken for the purposes
of immunohistochemical staining and microscopy, immune inﬁltrate ex-
traction andﬂow cytometric analysis, and/or RNA expression studies (see
SupplementaryMaterials andmethods). Microarray data were deposited
in Gene Expression Omnibus with accession number GSE61555.
3. Results
3.1. Clinical Response to Baricitinib
Soon after starting baricitinib treatment, there was a remarkable
improvement in the patient's AA, regressing to only a single patch of
hair loss on his occipital scalp three months after starting baricitinib
treatment (Fig. 1). There was a steady regrowth of hair on this single
patch, until he had complete resolution of hair loss nine months after
starting treatment (Fig. 1). With continued baricitinib treatment, his
hair regrowth persisted. Today, under baricitinib treatment, the patient
has complete hair growth on his scalp,with no signs of recurrence of AA.
3.2. Resolution of the IFN Signature
Intrigued by the rapid improvement in his AA, we evaluated the ef-
fect of baricitinib in a mouse model of AA and conducted mechanistic
studies to understand the action of baricitinib. We conducted three
sets of in vivo experiments to investigate the mechanisms of action of
baricitinib for AA. C3H/HeJ grafted alopecic mice were treated with
systemically administered baricitinib or vehicle/placebo control either
prior to (Supplementary Fig. 2) or following the establishment of alope-
cia (Supplementary Fig. 3). Furthermore, C3H/HeJ grafted alopecic mice
were treated with a topical formulation of baricitinib or vehicle control
after themice developed alopecia (Fig. 2). In all three cases, hair growth
was consistently observed in baricitinib-treated mice, compared with
no clinical evidence of hair regrowth in vehicle control treated mice
(Fig. 2 and Supplementary Figs. 2 and 3). Skin biopsies were taken
12 weeks after the start of treatment and assessed for immune cell
inﬁltration and loss of immune privilege. Baricitinib treated mice
exhibited substantially reduced inﬂammation as assessed by H&E
staining, reduced CD8 inﬁltration, and reduced MHC class I and class II
expression when compared with vehicle-control treated mice (Fig. 2).
CD8+NKG2D+ cells, critical effectors of disease in murine and human
AA, were greatly diminished in baricitinib treated mice compared
with vehicle control treated mice (Fig. 2).
To deﬁne the molecular response to baricitinib, we performed gene
expression proﬁling of treated skin in both the prevention and treat-
ment models. Our previous studies deﬁned an Alopecia Areata Disease
Activity Index (ALADIN) biomarker for response to treatment (Xing
et al., 2014), which monitors three distinct gene expression signatures,
one of which is the IFN response. In all three contexts, we observed
Fig. 1. Clinical response to baricitinib in CANDLE patient with AA. Scalp photos of the CANDLE patient with AA prior to and during treatment with baricitinib. Timeline showing the
approximate dates that photographs were taken and period in which the patient was being treated with baricitinib.
Fig. 2. Treatment of AA in C3H/HeJ mouse model. C3H/HeJ graft recipient mice were treated with topical baricitinib or vehicle control after disease establishment. A, Photographs were
taken at 12 weeks post-treatment. B, Graph of hair regrowth index in each group over time. C, Skin sections were taken at baseline and at 12 weeks post-treatment and stained with
H&E or with antibodies to CD8, MHC class I, MHC class II, or ICAM-1. D, Frequency of CD8+NKG2D+ cells in treated skin.
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Fig. 3. Normalization of IFN signature in baricitinib treated skin. A, Expression of indicated genes in skin and, B, ALADIN score plots, from C3H/HeJ grafted mice treated with topical
baricitinib or vehicle control administered after the establishment of disease demonstrating resolution of IFN and CTL scores with baricitinib treatment only. Yellow, control treatment
at week 0; orange, control treatment at week 12; red, baricitinib treatment at week 0; purple, baricitinib treatment at week 12.
354 A. Jabbari et al. / EBioMedicine 2 (2015) 351–355rapid normalization of the IFN gene expression signature in response to
baricitinib (Fig. 3 and Supplementary Figs. 2 and 3). Both the IFN and
cytotoxic T lymphocyte (CTL) components of the ALADIN strongly
discriminated between effectively treated mice and mice that did not
exhibit disease resolution.
4. Discussion
In this study, we report a dramatic clinical response to the JAK inhib-
itor baricitinib in a patient with longstanding AA. We further deﬁne the
mechanism of response to baricitinib and resolution of the IFN gene ex-
pression signature in the AAmousemodel. Recently, three independent
studies reported similar clinical responses to JAK inhibitors in patients
with AA. We recently showed that the JAK inhibitor ruxolitinib, which
also has relative selectivity for JAK1 and JAK2 and is currently approved
for myeloﬁbrosis, reversed disease in three AA patients in an open-label
clinical trial of oral drug in moderate-to-severe disease (Xing et al.,
2014). Secondly, a single patient with alopecia universalis and psoriasis
was treated orally with tofacitinib, an FDA approved JAK inhibitor with
higher afﬁnity to JAK3, and also showed a clinical response (Craiglow
and King, 2014). Lastly, a patient with essential thrombocythemia and
alopecia universalis was treated with ruxolitinib and exhibited striking
and near-complete hair regrowth after 10 months of treatment (Pieri
et al., 2015). Our previous studies using both ruxolitinib and tofacitinib
in the C3H/HeJ mouse model of AA demonstrated themolecular under-
pinnings of the response and resolution of the disease at the cellular and
molecular levels (Xing et al., 2014).
Small molecule JAK inhibitors offer several advantages when
compared with a therapeutic strategy centered on targeting cytokines
with biologics. First, small molecule JAK inhibitors have oral bioavail-
ability, making them more attractive to patients and likely increasing
adherence. Second, JAK inhibitors inhibitmultiple pathogenic pathways
simultaneously, including both type I and type II IFN receptor pathways,
both of which appear to be active in AA (Xing et al., 2014; Freyschmidt
Paul et al., 2006; Ghoreishi et al., 2010). Notably, small molecule JAK
inhibitors may be developed into a topical form in the future, with
two published studies examining the efﬁcacy of a topical JAK inhibitorfor the treatment of psoriasis (Ports et al., 2013; Punwani et al., 2012).
A topical JAK inhibitor may decrease the risk/beneﬁt proﬁle of this
class of drugs. Clinical trials examining the efﬁcacy of baricitinib in the
context of the compassionate use protocol for CANDLE syndrome as
well as for RA are currently underway. Results from a phase IIb clinical
trial for baricitinib in RA have been released showing a statistically
signiﬁcant improvement in ACR20 between baricitinib treatment and
placebo (Genovese et al., 2012), and phase III trials are currently under-
way for this indication. AA may represent another potential indication
for which baricitinib may be tested in the future. Taken together, the
recent reports of dramatic responses to treatment using JAK inhibitors
invite broader clinical exploration of the utility of these agents in AA.
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